Aldosterone antagonism in heart failure: Improvement of cardiac remodelling, endothelial dysfunction and platelet activation

European Journal of Clinical Investigation

Volumn 34, Issue 10, 2004, Pages 649-652

  Bauersachs, Johann ^a,b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; TRANDOLAPRIL;

DRUG EFFICACY; EDITORIAL; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE REMODELING; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; THROMBOCYTE ACTIVATION; VASCULAR ENDOTHELIUM;

ALDOSTERONE ANTAGONISTS; ENDOTHELIUM, VASCULAR; HEART FAILURE, CONGESTIVE; HUMANS; PLATELET ACTIVATION; VENTRICULAR REMODELING;

EID: 7044272109     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2004.01400.x     Document Type: Editorial

References (27)

1. Weber KT. Aldosterone in congestive heart failure. N Engl J Med 2001;345:1689-97.
2. Rouleau JL, Packer M, Moye L, de Champlain J, Bichet D, Klein M et al. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol 1994;24:583-91.
3. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 1990;82:1730-6.
4. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17.
5. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.
6. Silvestre JS, Heymes C, Oubenaissa A, Robert V, Aupetit-Faisant B, Carayon A et al. Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 1999;99:2694-701.
7. Satoh M, Nakamura M, Saitoh H, Satoh H, Akatsu T, Iwasaka J et al. Aldosterone synthase (CYP11B2) expression and myocardial fibrosis in the failing human heart. Clin Sci (Lond) 2002;102:381-6.
8. Mizuno Y, Yoshimura M, Yasue H, Sakamoto T, Ogawa H, Kugiyama K et al. Aldosterone production is activated in failing ventricle in humans. Circulation 2001;103:72-7.
9. Delyani JA, Robinson EL, Rudolph AE. Effect of a selective aldosterone receptor antagonist in myocardial infarction. Am J Physiol Heart Circ Physiol 2001;281:H647-H54.
10. Suzuki G, Morita H, Mishima T, Sharov VG, Todor A, Tanhehco EJ et al. Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation 2002;106:2967-72.
11. Fraccarollo D, Schäfer A, Hildemann S, Galuppo P, Ertl G, Bauersachs J. Additive Improvement of Left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. J Am Coll Cardiol 2003;42:1666-73.
12. Hayashi M, Tsutamoto T, Wada A, Tsutsui T, Ishii C, Ohno K et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 2003;107:2559-65.
13. Francis J, Weiss RM, Wei SG, Johnson AK, Beltz TG, Zimmerman K et al. Central mineralocorticoid receptor blockade improves Volume regulation and reduces sympathetic drive in heart failure. Am J Physiol Heart Circ Physiol 2001;281:H2241-51.
14. Barr CS, Lang CC, Hanson J, Arnott M, Kennedy N, Struthers AD. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995;76:1259-65.
15. Bauersachs J, Heck M, Fraccarollo D, Hildemann S, Ertl G, Wehling M et al. Addition of spironolactone to ACE inhibition in heart failure improves endothelial vasomotor dysfunction: Role of vascular superoxide anion formation and endothelial NO synthase expression. J Am Coll Cardiol 2002;39:351-8.
16. Schafer A, Fraccarollo D, Hildemann SK, Tas P, Ertl G, Bauersachs J. Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial dysfunction. Cardiovasc Res 2003;58:655-62.
17. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000;101:594-7.
18. Schäfer A, Fraccarollo D, Hildemann S, Christ M, Eigenthaler M, Kobsar A et al. Inhibition of platelet activation in congestive heart failure by selective aldsterone receptor antagonism and angiotensin converting enzyme inhibition. Thromb Haemostas 2003;89:1024-30.
19. Bauersachs J, Fraccarollo D, Ertl G, Gretz N, Wehling M, Christ M. Striking increase of natriuresis by low-dose spironolactone in congestive heart failure only in combination with ACE-inhibition: mechanistic evidence to support RALES. Circulation 2000;102:2325-8.
20. Virdis A, Neves MF, Amiri F, Viel E, Touyz RM, Schiffrin EL. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 2002;40:504-10.
21. Rajagopalan S, Duquaine D, King S, Pitt B, Patel P. Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 2002;105:2212-6.
22. Radomski MW, Palmer RM, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 1987;2:1057-8.
23. Anderson RA, Ellis GR, Chirkov YY, Holmes AS, Payne N, Blackman DJ et al. Determinants of platelet responsiveness to nitric oxide in patients with chronic heart failure. Eur J Heart Fail 2004;6:47-54.
24. Chirkov YY, Holmes AS, Martelli JD, Horowitz JD. Effect of perindopril on platelet nitric oxide resistance in patients with chronic heart failure secondary to ischemic left ventricular dysfunction. Am J Cardiol 2004;93:1438-40.
25. O'Connor CM, Gurbel PA, Serebruany VL. Usefulness of soluble and surface-bound P-selectin in detecting heightened platelet activity in patients with congestive heart failure. Am J Cardiol 1999;83:1345-9.
26. Stumpf C, Lehner C, Eskafi S, Raaz D, Yilmaz A, Ropers S et al. Enhanced levels of CD154 (CD40 ligand) on platelets in patients with chronic heart failure. Eur J Heart Fail 2003;5:629-37.
27. Bauersachs J, Fraccarollo D. Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure. Minerva Cardioangiol 2003;51:155-64.